Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Analysts expect sale of AAH arm

Clare Dobie,City Editor
Thursday 17 June 1993 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

AAH, the UK's largest drugs wholesaler, is expected to sell its builders' merchanting business, which no longer fits with the rest of the group.

Analysts expect the company, which yesterday announced a small drop in profits to pounds 37.3m before tax in the year to 31 March, to dispose of the division, which accounted for just 5 per cent of trading profits.

Bill Revell, the chief executive, declined to comment on the future of the division but said: 'Everything is for sale at a price.'

UK pharmaceutical wholesaling contributed pounds 22.8m, down from pounds 19.6m, or more than half group trading profits. The result was helped by the absorption of Medicopharma's wholesaling business.

Mr Revell said prospects would be boosted if more hospitals gave up bulk buying and switched instead to purchasing supplies from distributors who can make small deliveries as needed.

The British Association of Pharmaceutical Wholesalers has estimated that this would cut the hospital drugs bill by pounds 150m a year. Mr Revell estimates that similar savings are possible on surgical supplies.

Group sales rose 12 per cent to pounds 1.4bn. Pre-exceptional profits rose 15.7 per cent to pounds 41.9m. Pre-tax profits in 1992 were boosted by a pounds 6.6m exceptional profit on the sale of Weevsown, without which 1993 taxable profits would have risen 16 per cent.

The final dividend is up 5 per cent to 11.5p a share, taking the total for the year to 17.3p, up by 5.8 per cent. Earnings per share rose by 3 per cent, under FRS3, the latest accounting standard. The shares rose 14p to 517p.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in